Kim Linton

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski et al. · The Lancet Haematology · 2016 · 599 citations · Full text

Medicine, Immunology, Oncology +12

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial

Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski et al. · The Lancet Haematology · 2017 · 381 citations · Full text

Medicine, Immunology, Oncology +17

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Martin Hutchings, Rogier Mous, Michael Roost Clausen et al. · The Lancet · 2021 · 337 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma

M. Dreyling, Franck Morschhauser, Krimo Bouabdallah et al. · Annals of Oncology · 2017 · 272 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Guidelines for the management of diffuse large B‐cell lymphoma

Sridhar Chaganti, Tim Illidge, Sally F. Barrington et al. · British Journal of Haematology · 2016 · 166 citations · Full text

Medicine, Hematology, Oncology +14